CADL - Candel Therapeutics, Inc. Quarterly EPS earnings growth

Candel Therapeutics, Inc. (CADL) - corporate logo

Quarterly earnings per share growth helps assess Candel Therapeutics (CADL) strategy of creating patent-protected viral brain drugs. The current parameter is -37.00, which is critical given the absence of stable cash flow due to the trial stage. Since the development of immunotherapy is independent of economic cycles, the indicator's dynamics highlight the fundamental value of the research regardless of macroeconomic shocks.

candeltx.com (CADL) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for candeltx.com (CADL)

- market value and analyst target forecast:
Price Chart Candel|CADL - Fair Value Consensus
- market capitalization statistics:
Market Capitalization Candel|CADL - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Candel Therapeutics|CADL - Company Net Assets|Market Capitalization to Book Value Ratio candeltx.com|CADL - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Candel Therapeutics|CADL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Candel Therapeutics|CADL - Company Aggregate Debt|Debts to Book Capitalization Candel|CADL - Long-Term Debt|Company Short-Term Debt Candel Therapeutics|Quick Liquidity Indicator candeltx.com
- earnings and valuation multiples indicators:
CADL - Final Profit|Future Profit Candel Therapeutics|CADL - Market Price to Net Income Ratio|Forward P/E Multiple Candel|CADL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Candel|CADL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Candel Therapeutics|CADL - Earnings per share for the trailing year|Quarterly EPS earnings growth candeltx.com|CADL - Earnings growth in current year|Net earnings per share growth forecast for next year Candel Therapeutics
- revenue and sales proceeds data:
CADL - Company Annual Revenue|Projected Sales Volume candeltx.com|CADL - Price to Sales|Forward Price-to-Revenue Multiple Candel Therapeutics, Inc.
Summary company analysis:Candel Therapeutics Inc. - CADL
Manufactured product of Candel Therapeutics

Assessing the operational resilience of an asset begins with an analysis of net profit dynamics. For Candel Therapeutics (CADL), proprietary oncolytic viruses and breakthroughs in cancer therapy serve as key drivers. Quarterly EPS growth measures the rate of change in earnings per share over three months, transforming data into a trend. The current value of -37.00 reflects the fundamental efficiency of the business. A positive trajectory confirms the commercial potential of these innovative developments.

Analysis of competing companies

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)